BTIG Maintains Buy on Kazia Therapeutics, Raises Price Target to $40

Benzinga Newsdesk www.benzinga.com Positive 84.1%

Neg 0% Neu 0% Pos 84.1%

BTIG analyst Kambiz Yazdi maintains Kazia Therapeutics (NASDAQ:KZIA) with a Buy and raises the price target from $34 to $40.